Literature DB >> 3540216

Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer.

A Twijnstra, A P van Zanten, W J Nooyen, B W Ongerboer de Visser.   

Abstract

The clinical efficacy of four laboratory tests in detecting leptomeningeal metastases in 57 patients with breast carcinoma was assessed. The sensitivity and specificity of beta-glucuronidase, beta 2-microglobulin, carcinoembryonic antigen and lactate dehydrogenase in cerebrospinal fluid were determined. As a single test beta-glucuronidase was the most sensitive (93%) and specific (93%) for discriminating between leptomeningeal metastases and other CNS metastases from breast cancer. Lactate dehydrogenase was the next most useful marker. Both beta 2-microglobulin and carcinoembryonic antigen had a sensitivity of 60%. More specific results were achieved by combining beta-glucuronidase and lactate dehydrogenase. CSF beta-glucuronidase may be useful by itself and in combination with lactate dehydrogenase in the detection of leptomeningeal metastases from breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3540216      PMCID: PMC1029072          DOI: 10.1136/jnnp.49.11.1246

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  12 in total

1.  Radioimmune assay of carcinoembryonic antigen.

Authors:  M L Egan; J T Lautenschleger; J E Coligan; C W Todd
Journal:  Immunochemistry       Date:  1972-03

2.  Lactate dehydrogenase and glutamic oxalacetic transaminase of the cerebrospinal fluid in tumours of the central nervous system.

Authors:  G A Davies-Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-08       Impact factor: 10.154

3.  CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer.

Authors:  B S Yap; H Y Yap; H A Fritsche; G Blumenschein; G P Bodey
Journal:  JAMA       Date:  1980-10-03       Impact factor: 56.272

4.  Cerebrospinal fluid beta 2-microglobulin: a study in controls and patients with metastatic and non-metastatic neurological diseases.

Authors:  A Twijnstra; A P van Zanten; W J Nooyen; A A Hart; B W Ongerboer de Visser
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

5.  Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology.

Authors:  J P Glass; M Melamed; N L Chernik; J B Posner
Journal:  Neurology       Date:  1979-10       Impact factor: 9.910

6.  CSF beta-glucuronidase assay in the diagnosis of neoplastic meningitis.

Authors:  E Shuttleworth; N Allen
Journal:  Arch Neurol       Date:  1980-11

7.  Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination.

Authors:  G M Mavlight; S E Stuckey; F F Cabanillas; M J Keating; W W Tourtellotte; S C Schold; E J Freireich
Journal:  N Engl J Med       Date:  1980-09-25       Impact factor: 91.245

8.  Distribution of beta2-microglobulin in cerebrospinal fluid and in cystic fluid of brain tumors. A preliminary study.

Authors:  C Schaub; M T Bluet-Pajot; G Szikla; C Lornet-Videau; F Mounier; J Talairach
Journal:  Pathol Biol (Paris)       Date:  1978-09

9.  Cerebrospinal fluid biochemical markers of central nervous system metastases.

Authors:  S C Schold; W R Wasserstrom; M Fleisher; M K Schwartz; J B Posner
Journal:  Ann Neurol       Date:  1980-12       Impact factor: 10.422

10.  Carcinoembryonic antigen estimation in cerebrospinal fluid in patients with metastatic breast cancer.

Authors:  D P Dearnaley; S Patel; T J Powles; R C Coombes
Journal:  Oncodev Biol Med       Date:  1981
View more
  6 in total

1.  Contribution of CSF cytology in the diagnostic work-up of breast cancer patients with neurological symptoms: a retrospective analysis over two decades.

Authors:  C A P Wauters; J Poelen; I Mulder; D Venderink; L J A Strobbe; P Wesseling
Journal:  J Neurooncol       Date:  2012-01-04       Impact factor: 4.130

Review 2.  Breast leptomeningeal disease: a review of current practices and updates on management.

Authors:  Nicholas B Figura; Victoria T Rizk; Avan J Armaghani; John A Arrington; Arnold B Etame; Hyo S Han; Brian J Czerniecki; Peter A Forsyth; Kamran A Ahmed
Journal:  Breast Cancer Res Treat       Date:  2019-06-17       Impact factor: 4.872

Review 3.  Novel methods to diagnose leptomeningeal metastases in breast cancer.

Authors:  Lindsay Angus; John W M Martens; Martin J van den Bent; Peter A E Sillevis Smitt; Stefan Sleijfer; Agnes Jager
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

Review 4.  The Utility of Liquid Biopsy in Central Nervous System Malignancies.

Authors:  Kathryn S Nevel; Jessica A Wilcox; Lindsay J Robell; Yoshie Umemura
Journal:  Curr Oncol Rep       Date:  2018-06-06       Impact factor: 5.075

Review 5.  Recent Advancements of Treatment for Leptomeningeal Carcinomatosis.

Authors:  Ho-Shin Gwak; Sang Hyun Lee; Weon Seo Park; Sang Hoon Shin; Heon Yoo; Seung Hoon Lee
Journal:  J Korean Neurosurg Soc       Date:  2015-07-31

6.  Diagnostic Value of CYFRA 21-1 in the Cerebrospinal Fluid for Leptomeningeal Metastasis.

Authors:  Zhen Zhang; Chenglin Tian; Qiang Shi; Jing Hao; Na Zhao; Zhijie Liu
Journal:  Dis Markers       Date:  2017-02-19       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.